FlexiLingo
Montana’s plan to become an experimental medical hub are moving forward
The state’s effort to expand the “right to try” is making headway, and the first drugs are about to be reviewed. This story was written by Jessica Hamzelou and narrated by Noa - newsoveraudio.com. Listen to more of the world's best journalism on the Noa app.
打开播放器：完整文字稿，每个单词都可点击，附翻译和单词卡。
这一集适合你吗？
B2 · 中高级
能看懂电视新闻就会觉得轻松
- 73% 的单词在 B1 或更简单的水平。
- 每分钟 134 词：自然语速。
- 整集共有 124 个较难的单词（B2 及以上）。
试一试：点任意单词
来自本集开头的真实句子，每个单词都标出了难度级别。
点一个单词，用你的语言查看释义。
这些单词你认识吗？
本集中 8 个较难的单词。点一个查看释义，然后标记一下。
标记几个单词，我们会告诉你这一集是否适合你的水平。
这一集适合你吗？
B2 · 中高级
能看懂电视新闻就会觉得轻松
- 73% 的单词在 B1 或更简单的水平。
- 每分钟 134 词：自然语速。
- 整集共有 124 个较难的单词（B2 及以上）。
文字稿
本集开头部分。完整文字稿在播放器中。
较难的单词（B2+）
Welcome to MIT Technology Review Narrated. My name is Matt Honin. I'm our Editor-in-Chief. Every week, we'll bring you a fascinating, new, in-depth story from the leading edge of science and technology, covering topics like AI, biotech, climate, energy, robotics, and more. Here's this week's story. I hope you enjoy it.
Jessica Hamzalu writes, Montana's plan to become an experimental medical hub just pushed forward. As of July 2026 in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers.
Companies whose drugs have been through preliminary testing, sometimes in as few as 10 healthy people can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the company can set the price of the drug and sell it via experimental treatment clinics, the first of which is likely to be up and running around
以上是开头部分。 本集其余部分（16 分钟）在播放器中：每个单词都可点击，附翻译、生词收藏和单词卡。
在播放器中继续由音频自动生成，可能存在错误。 音频版权归其发布者所有，并从其订阅源播放。版权所有者可申请删除 — 版权与删除政策